Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

Kite Phar­ma just got FDA ap­proval to kick off op­er­a­tions at a new man­u­fac­tur­ing cam­pus.

The can­cer-fo­cused, CAR-T cell ther­a­py play­er made the an­nounce­ment Mon­day, say­ing that the fed­er­al reg­u­la­to­ry agency gave the green light to Kite’s 100,000 square-foot, retro­vi­ral vec­tor man­u­fac­tur­ing fa­cil­i­ty in Ocean­side, CA.

Kite’s glob­al head of tech­ni­cal op­er­a­tions Chris Mc­Don­ald tells End­points News that the fa­cil­i­ty has been in the works for about four years, af­ter Kite teamed up with its par­ent com­pa­ny Gilead. Gilead ac­quired Kite Phar­ma for just shy of $12 bil­lion in 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.